Stay updated on Pralsetinib vs Standard of Care in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The change on the webpage represents an update in the Participation Criteria section, specifically focusing on eligibility criteria for participants with non-small cell lung cancer (NSCLC) who have not received systemic anticancer therapy for metastatic disease. The criteria now include requirements such as pathologically confirmed NSCLC, documented RET-fusion, measurable disease based on RECIST 1.1, and an ECOG Performance Status of 0 or 1.
    Difference
    18%
    Check dated 2024-05-22T07:44:38.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    18 days ago
    Change Detected
    Summary
    The value for the Primary Completion date has recently changed from (Estimated) to 2025-06-30. This change indicates a potential update in the expected completion date of the study on Pralsetinib versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer.
    Difference
    0.0%
    Check dated 2024-05-07T19:59:31.000Z thumbnail image
  7. Check
    20 days ago
    Change Detected
    Summary
    The value '03 29' has been changed to '05 06'. This change possibly indicates an update or shift in the study timeline or schedule related to the medical trial mentioned on the webpage.
    Difference
    6%
    Check dated 2024-05-06T17:25:43.000Z thumbnail image
  8. Check
    25 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:21:42.000Z thumbnail image

Stay in the know with updates to Pralsetinib vs Standard of Care in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page.